All In Biotech

Drug Trial Radar · NCT03836287

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)

A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects With Axillary Hyperhidrosis

Last checked: Nov 20, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Oct 9, 2020

Primary completion

Jun 25, 2021

Study completion Jun 25, 2021

Sponsor

Lead sponsor
Botanix PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 11, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of the sweat glands. Current therapies have limited effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide (BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis. This Phase 3 study will assess the safety and efficacy of sofpironium bromide, 15% gel versus vehicle (2 treatment arms), applied for the treatment of axillary hyperhidrosis.

Conditions

  • Axillary Hyperhidrosis

Interventions

  • Sofpironium Bromide Gel, 15%Drug

    Active

  • VehicleDrug

    Vehicle gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity Measure-Axillary-7 Item Total Score From Baseline to End of TreatmentTime frame: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.
  2. Observed Change in Participant (Vehicle Arm vs SB Gel 15% Arm) Ranked Gravimetric Sweat Production From Baseline to End of TreatmentTime frame: Total Trial Participation was approximately 11-15 weeks; outcome measure time frame: Baseline (and treatment start) through to end of treatment, taking approximately 6 weeks.

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center, P.C.

    Birmingham, Alabama

  • Investigate MD, LLC

    Scottsdale, Arizona

  • Northwest Arkansas Clinical Trials Center

    Rogers, Arkansas

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • Dermatology Research Associates

    Los Angeles, California

  • Therapeutics Clinical Research

    San Diego, California

  • Clinical Science Institute

    Santa Monica, California

  • AboutSkin Research, LLC

    Greenwood Village, Colorado

  • Center for Clinical & Cosmetic Research

    Aventura, Florida

  • Skin Care Research, LLC

    Boca Raton, Florida

  • Skin Research Institute

    Coral Gables, Florida

  • Finlay Medical Research

    Greenacres City, Florida

  • Aby's New Generation Research

    Hialeah, Florida

  • Baumann Cosmetic and Research Institute

    Miami, Florida

  • International Dermatology Research, Inc.

    Miami, Florida

  • My Community Research Center, Inc.

    Miami, Florida

  • Tory Sullivan, MD PA

    North Miami Beach, Florida

  • Research Institute of the Southeast

    West Palm Beach, Florida

  • Dawes Fretzin Research Group

    Indianapolis, Indiana

  • Maryland Laser Skin and Vein

    Hunt Valley, Maryland

  • Lawrence J Green, MD LLC

    Rockville, Maryland

  • SkinCare Physicians

    Chestnut Hill, Massachusetts

  • Grekin Skin Institute

    Warren, Michigan

  • Minnesota Clinical Study Center

    New Brighton, Minnesota

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • Skin Specialists, P.C.

    Omaha, Nebraska

  • Hassman Research Institute

    Berlin, New Jersey

  • DermResearch Center of New York, Inc.

    Stony Brook, New York

  • PMG Research of Cary

    Raleigh, North Carolina

  • Haber Dermatology and Cosmetic Surgery, Inc.

    Beachwood, Ohio

  • Oregon Dermatology & Research Center

    Portland, Oregon

  • Clinical Research Center of the Carolinas

    Charleston, South Carolina

  • Tennessee Clinical Research Center

    Nashville, Tennessee

  • DermResearch, Inc.

    Austin, Texas

  • Austin Institute for Clinical Research, Inc.

    Pflugerville, Texas

  • Progressive Clinical Research

    San Antonio, Texas

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas

  • Virginia Clinical Research, Inc.

    Norfolk, Virginia

  • Dermatology Associates of Seattle

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.